Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
W Sakai, EM Swisher, BY Karlan, MK Agarwal… - Nature, 2008 - nature.com
Ovarian carcinomas with mutations in the tumour suppressor BRCA2 are particularly
sensitive to platinum compounds 1 . However, such carcinomas ultimately develop cisplatin …
sensitive to platinum compounds 1 . However, such carcinomas ultimately develop cisplatin …
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer
…, SM Domchek, BK Arun, KH Lu, G Mitchell, BY Karlan… - Jama, 2015 - jamanetwork.com
Importance Limited information about the relationship between specific mutations
inBRCA1orBRCA2(BRCA1/2) and cancer risk exists. Objective To identify mutation-specific cancer …
inBRCA1orBRCA2(BRCA1/2) and cancer risk exists. Objective To identify mutation-specific cancer …
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
Breast cancer susceptibility variants frequently show heterogeneity in associations by tumor
subtype 1 , 2 – 3 . To identify novel loci, we performed a genome-wide association study …
subtype 1 , 2 – 3 . To identify novel loci, we performed a genome-wide association study …
Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology
…, S Friedman, M Goggins, ML Hutton, BY Karlan… - Journal of the National …, 2021 - jnccn.org
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated …
Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated …
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
…, V Heong, DG Huntsman, M Iwanicki, BY Karlan… - Nature reviews …, 2015 - nature.com
High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths,
and overall survival has not changed significantly for several decades. In this Opinion article…
and overall survival has not changed significantly for several decades. In this Opinion article…
Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature
Major risks conferred by BRCA1 and BRCA2 in women are for cancers of the breast, ovary,
fallopian tube, and peritoneum. Male carriers of mutations in BRCA1 or BRCA2 are also …
fallopian tube, and peritoneum. Male carriers of mutations in BRCA1 or BRCA2 are also …
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation …
…, TQ Pham, RC Dere, BY Karlan - Journal of Clinical …, 2006 - ascopubs.org
Purpose Ovarian cancers (OCs) frequently have HER2 activation in the absence of HER2
overexpression. Pertuzumab, a humanized antibody that prevents HER2 dimerization and …
overexpression. Pertuzumab, a humanized antibody that prevents HER2 dimerization and …
Ovarian cancer
…, BE Howitt, J Sehouli, BY Karlan - Nature reviews Disease …, 2016 - nature.com
Ovarian cancer is not a single disease and can be subdivided into at least five different
histological subtypes that have different identifiable risk factors, cells of origin, molecular …
histological subtypes that have different identifiable risk factors, cells of origin, molecular …
Improved survival in women with BRCA‐associated ovarian carcinoma
…, R Moslehi, SA Narod, BY Karlan - … Journal of the …, 2003 - Wiley Online Library
BACKGROUND The objective of this study was to determine the clinical characteristics,
treatment response, and frequency of p53 overexpression in Ashkenazi Jewish women with …
treatment response, and frequency of p53 overexpression in Ashkenazi Jewish women with …
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer
Context Approximately 10% of women with invasive epithelial ovarian cancer (EOC) carry
deleterious germline mutations in BRCA1 or BRCA2. A recent article suggested that BRCA2 -…
deleterious germline mutations in BRCA1 or BRCA2. A recent article suggested that BRCA2 -…